Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Bladder Disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A non-neoplastic or neoplastic disorder affecting the urinary bladder. A representative example of non-neoplastic bladder disorder is bacterial bladder infection. A representative example of neoplastic bladder disorder is bladder carcinoma.
Novel agents for preventing and treating disorders involving modulation of the RyR receptors
InactiveUS20070049572A1Improve bindingLow affinityBiocideOrganic active ingredientsSIDS - Sudden infant death syndromeDisease cause
The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Novel agents for preventing and treating disorders involving modulation of the RyR receptors
ActiveUS20060194767A1BiocideOrganic active ingredientsSIDS - Sudden infant death syndromeCognitive disorder
The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism
This invention describes a new combination for the treatment of functional bladder disorders which comprises a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism.
Owner:BOEHRINGER INGELHEIM INT GMBH
Non-invasive electrical and magnetic nerve stimulators used to treat overactive bladder and urinary incontinence
Transcutaneous electrical and magnetic nerve stimulation devices and methods generate energy that is delivered noninvasively to selected nerve fibers within the patient to treat lower urinary tract disorders. The disorders comprise overactive bladder, urge incontinence, stress, incontinence, urge frequency, non-obstructive urinary retention and interstitial cystitis / painful bladder syndrome. In preferred embodiments, a posterior tibial nerve of a patient is stimulated non-invasively to treat bladder disorders.
Owner:ELECTROCORE
Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
This invention describes a new combination for the treatment of functional bladder disorders which comprises an alpha antagonist and / or 5-alpha-reductase inhibitor and a beta-3-adrenoceptor agonist.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents
A pharmaceutical composition useful in the treatment of functional bladder disorders comprising an antimuscarinic agent and a beta-3-adrenoceptor agonist is described.
Owner:BOEHRINGER INGELHEIM INT GMBH
Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
InactiveUS20070122466A1Reduce and prevent antibody-mediated resistanceIncrease stimulationLiposomal deliveryAgainst vector-borne diseasesDiseaseLipid formation
The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and / or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.
Owner:UNIVERSITY OF PITTSBURGH
Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
InactiveUS8110217B2Reduce and prevent antibody-mediated resistanceIncrease stimulationLiposomal deliveryAgainst vector-borne diseasesDiseaseMetabolite
Owner:UNIVERSITY OF PITTSBURGH
Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints
This invention relates to the use of beta-3-adrenoceptor agonists for the prevention and treatment of kidney damage and / or functional bladder complaints, particularly bladder complaints of neurogenic origin as the result of spinal cord injury.
Owner:MICHEL MARTIN C
Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
This invention describes a new combination for the treatment of functional bladder disorders which comprises alpha agonists and a beta-3-adrenoceptor agonist.
Owner:BOEHRINGER INGELHEIM INT GMBH
Method of treating bladder disorders
ActiveUS20130253067A1Increase micturition intervalIncrease mean voided volumeBiocideAntimycoticsDexmecamylamineDisease
The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder.
Owner:TARGACEPT INC
Detection of neureopeptides associated with pelvic pain disorders and uses thereof
InactiveUS20080070239A1Effective treatmentRelieve symptomsOrganic active ingredientsBiocideDense Core VesiclesSensory neuron
Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic nonhuman model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1
Compositions and methods for the modulation of detrusor activity
InactiveUS20080089884A1BiocideSsRNA viruses positive-senseMIF receptorMacrophage migration inhibition
The invention relates generally to methods for treating and / or preventing bladder disorders. In certain embodiments the invention comprises methods for the treatment and / or prevention of a bladder disorder comprising administering an effective amount of a therapeutic agent that decreases the expression, release or biological activity of macrophage migration inhibition factor (MIF) to a subject in need thereof. In other aspects the invention relates to a method for diagnosing bladder disease and / or bladder disease severity comprising screening for a MIF gene or MIF receptor gene polymorphism or expression level.
Owner:YALE UNIV +1
Detection of neuropeptides associated with pelvic pain disorders and uses thereof
InactiveUS20120058950A1Effective to treat the pelvic pain disorderRelieve symptomsBiocideOrganic active ingredientsDense Core VesiclesSensory neuron
Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic non-human model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1
Penisster system
InactiveUS20020134389A1Pleasant for wearerComfortably insertedMale contraceptivesSurgeryDiseasePenis
The medical system 10 is an article of cloth, rubber and elastic made in the style of a pair of briefs, the front of the system 10 is made of a rubber material in the form of a shield 40 covered with cloth to protect direct contact from bodies of both partners in case of sexual activities. Attached to the shield 40 is namely a hollow tubal-shaped device 42 to be worn over the penis. The tubal-shaped device 42 has a nipple 53 at the end and can be used for sexual activities. The medical system 10 a pouch 56 beneath tubular-shaped device 42 to store device 42. Persons with prostate and bladder disorder may also use this medical system 10 for incontinence.
Owner:BADGETT HENRY O
Penisster system
The medical system 10 is an article of cloth, rubber and elastic made in the style of a pair of briefs, the front of the system 10 is made of a rubber material in the form of a shield 40 covered with cloth to protect direct contact from bodies of both partners in case of sexual activities. Attached to the shield 40 is namely a hollow tubal-shaped device 42 to be worn over the penis. The tubal-shaped device 42 has a nipple 53 at the end and can be used for sexual activities. The medical system 10 a pouch 56 beneath tubular-shaped device 42 to store device 42. Persons with prostate and bladder disorder may also use this medical system 10 for incontinence.
Owner:BADGETT HENRY O
Agents for preventing and treating disorders involving modulation of the RyR receptors
InactiveUS7704990B2BiocideOrganic active ingredientsVentricular dysrhythmiaSIDS - Sudden infant death syndrome
The present invention provides novel compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Agents for preventing and treating disorders involving modulation of the RyR receptors
ActiveUS8022058B2Organic active ingredientsBiocideVentricular dysrhythmiaSIDS - Sudden infant death syndrome
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Treatment of bladder diseases with a tlr7 activator
The invention provides a method for the treatment of superficial bladder cancer and inflammatory diseases of the bladder which employs certain Toll-like Receptor (TLR)-agonists.
Owner:UNIV OF CALIFORNIA LOS ANGELES +1
Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds
InactiveUS20090163453A1Reduce adverse effectsStrong therapeutic activityBiocideOrganic active ingredientsDiseaseHigh doses
The present invention relates to a method for preventing, treating, or ameliorating gastrointestinal and bladder disorders in a patient receiving a chemotherapy or radiation therapy comprising administering to the patient a therapeutically effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or a mimic thereof may be administered by high dose pulse administration so that high doses of the active vitamin D compound or a mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia.
Owner:NOVACEA INC
Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
InactiveUS20170290773A1Reduce and prevent antibody-mediated resistanceIncrease stimulationUrinary disorderLiposomal deliveryDiseaseMetabolite
The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and / or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
Owner:UNIVERSITY OF PITTSBURGH
Method of treating bladder disorders
The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder.
Owner:TARGACEPT INC
Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
A method for maintaining and / or enhancing the efficacy of a pharmaceutically active agent in a sustained-release treatment of a bladder disorder is disclosed. In preferred embodiments, the pharmaceutically active agent is botulinum toxin. The method comprises obtaining a biocompatible mucoadhesive thermoreversible hydrogel; and incorporating said pharmaceutically active agent for treatment of a bladder disorder into said biocompatible mucoadhesive thermoreversible hydrogel. The use of a biocompatible mucoadhesive thermoreversible hydrogel comprising a pharmaceutically active agent such as botulinum toxin in the treatment of bladder disorders, and a method for treating bladder disorders by the use of such a composition that does not require injection of the pharmaceutically active agent into the bladder wall, are also disclosed.
Owner:THERACOAT
Methods Using Sulodexide for the Treatment of Bladder Disease
InactiveUS20070173479A1Reducing and preventing symptomPreventing and reducing and and complicationBiocideOrganic active ingredientsInterstitial cystitisSulodexide
The present invention concerns methods for the treatment of bladder related diseases and, in particular, inflammatory bladder diseases such as interstitial cystitis, by administration of sulodexide.
Owner:KERYX BIOPHARMLS
Pharmaceutical composition for the treatment of bladder disorders
The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and / or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.
Owner:RICHTER GEDEON NYRT
Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
This invention describes the use of beta-3-adrenoceptor agonists for the treatment of functional bladder disorders, particularly stress incontinence and / or mixed incontinence.
Owner:BOEHRINGER INGELHEIM INT GMBH
Methods of treating bladder disorders
InactiveUS20050282763A1Reduced antibody productionReduced histamine releaseDepsipeptidesGranular deliveryBladder cancerMammal
Methods of treating bladder disorders, including bladder cancer and inflammatory bladder diseases such as interstitial cystitis are disclosed. The methods include identifying a mammal that has or is at risk for having a bladder disorder and administering isolated nucleic acid sequences to the mammal. Nucleic acids used in the methods of the invention contain unmethylated CpG sequences, which are thought to modulate the immune response. Also included are methods that use nucleic acids encoding alpha-MSH. The nucleic acid sequences may be administered individually or together or can be included in the same nucleic acid.
Owner:ZYCOS A MASSACHUSETTS CORP
Composition for treatment of overactive bladder
ActiveUS20210051989A1Conserve testosteroneMuscle strengtheningUrinary disorderFood scienceNutrition supplementationNutrition
A nutritional supplement composition for treatment of bladder disorders, in particular, overactive bladder (OAB) includes therapeutically effective amounts of pumpkin seed extract, nitric oxide precursor, vitamin D3, prebiotic fiber, preservative, and stabilizer.
Owner:BELLER MICHAEL
Pharmaceutical composition for the treatment of bladder disorders
The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and / or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.
Owner:RICHTER GEDEON NYRT
Bladder disease monitor
InactiveCN109893114ANovel module structureWorking principle is clearDiagnostic recording/measuringSensorsDiseaseFull bridge
The invention provides a bladder disease monitor, and belongs to the technical field of medical equipment. The bladder disease monitor comprises a lithium ion battery, a sensor conditioning circuit, acontroller and a touch display screen; the lithium ion battery is connected with a 5V voltage stabilizing circuit, and the 5V voltage stabilizing circuit is connected with a resistor stress sensor, adifferential full-bridge conditioning circuit, a 24-bit AD conversion module and a 32-bit single chip controller; the 32-bit single chip controller is connected with the 24-bit AD conversion module,the touch screen and an external storage; and the lithium ion battery provides a portable rechargeable power source for a whole system, through an SD card storage technology, the system can store larger volume of data, and the stability and reliability of data storage are improved. The bladder disease monitor is novel in module structure and clear in working principle, design is conducted by taking the single chip microcomputer STM32F103RCT6 as a core, operation is easy and convenient, trauma is small, the cost is low, the bladder pressure is monitored on line, the bladder disease monitor hasthe advantages of short measuring time, accurate data, high automatic degree and the like, medical workers grasp the condition of patients in time conveniently, and the great application value is achieved.
Owner:徐州天荣医疗通讯设备有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com